Open AccessSwitching on the green light for chimeric antigen receptor T‐cell therapy
Author(s) -
Mardiana Sherly,
Lai Junyun,
House Imran Geoffrey,
Beavis Paul Andrew,
Darcy Phillip Kevin
Publication year - 2019
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1002/cti2.1046
Subject(s) - chimeric antigen receptor , reprogramming , context (archaeology) , cell therapy , cancer research , genetic enhancement , immune system , tumor microenvironment , immunology , transgene , antigen , t cell , adoptive cell transfer , biology , medicine , cell , gene , genetics , paleontology
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor ( CAR ) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T‐cell therapy in a subset of B‐cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene‐modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.